BioHarvest Lands $1.4M Non-Dilutive Grant for AI-Driven Plant-Cell R&D
BHST is trading near its 52-week low of $2.7 (0.0% above the low).
Summary
BioHarvest secured a $1.4M grant from the Israel Innovation Authority to integrate AI and machine learning into its plant-cell synthesis R&D. The non-dilutive, zero-interest loan is repayable only from future project revenues, strengthening the company's cash position without equity dilution. This is the second IIA grant this year, following a manufacturing-focused award, and together they aim to transform both early-stage discovery and commercial production. With a market cap near $63M and shares trading at 52-week lows, the non-dilutive funding provides a modest but timely boost to the company's financial runway.
At the time of this announcement, BHST was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.2M. The 52-week trading range was $2.70 to $12.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.